My Size : PROSPECTUS SUPPLEMENT (To the Prospectus dated December 30, 2020)

Filed Pursuant to Rule 424(b)(5)

Registration No. 333-251679

PROSPECTUS SUPPLEMENT

(To the Prospectus dated December 30, 2020)

My Size, Inc.

162,000 Shares of Common Stock

Pre-Funded Warrants to Purchase up to 279,899 Shares of Common Stock

We are offering 162,000 shares of common stock to a certain institutional investor at an offering price of $3.055 per share and pre-funded warrants to purchase up to 279,899 shares of common stock at an offering price of $3.054 per pre-funded warrant, pursuant to this prospectus supplement and the accompanying prospectus. Each registered pre-funded warrant will be exercisable for one share of common stock at an exercise price of $0.001 per share, will be immediately exercisable, and will not expire until fully exercised. We are also offering pursuant to this prospectus supplement and the accompanying prospectus the shares of common stock issuable upon the exercise of the pre-funded warrants.

In concurrent private placements to the same institutional investor, we are issuing (i) unregistered pre-funded warrants to purchase an aggregate of 540,098 shares of common stock at an offering price of $3.054 per pre-funded warrant, and (ii) unregistered Series A warrants to purchase up to an aggregate of 981,997 shares of common stock and Series B warrants to purchase up to an aggregate of 981,997 shares of common stock, in which for each share or pre-funded warrant issued in this offering and the private placement, an associated Series A and Series B warrant is being issued. The unregistered pre-funded warrants have an exercise price of $0.001 per share, will be immediately exercisable upon issuance, and will not expire until fully exercised. Each Series A warrant and Series B warrant will be exercisable for one share of common stock at an exercise price of $2.805 per share and will be immediately exercisable upon issuance. The Series A warrants will expire five and one-half years from the initial exercise date and the Series B warrants will expire 28 months from the initial exercise date. The unregistered pre-funded warrants, the unregistered Series A and B warrants and the shares of common stock issuable upon the exercise of such unregistered warrants are being offered pursuant to the exemptions provided in Section 4(a)(2) under the Securities Act of 1933, as amended, or the Securities Act, and Rule 506(b) promulgated thereunder, and they are not being offered pursuant to this prospectus supplement and the accompanying prospectus. The registered and unregistered warrants are not and will not be listed for trading on any national securities exchange.

Our common stock is listed on the Nasdaq Capital Market under the symbol "MYSZ" and on the Tel Aviv Stock Exchange, or the TASE, under the symbol "MYSZ". On January 9, 2023, the last reported sale price of our common stock on the Nasdaq Capital Market was $2.84 per share.

The aggregate market value of our outstanding common stock held by non-affiliates pursuant to General Instruction I.B.6 of Form S-3 was approximately $1.84 million, which was calculated based on 1,464,117 shares of common stock outstanding of which 1,163,674 shares were held by non-affiliates, and a price per share of $4.75 which was the closing sale price of our common stock on the Nasdaq Capital Market on December 8, 2022. We have not sold any of our securities pursuant to General Instruction I.B.6. of Form S-3 during the prior 12 calendar month period that ends on and includes the date hereof (but excluding this offering).

Investing in our securities involves a high degree of risk. You should read this prospectus supplement and the accompanying prospectus as well as the information incorporated herein and therein by reference carefully before you make your investment decision. See "Risk Factors" beginning on page S-6 of this prospectus supplement and on page 3 of the accompanying prospectus.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement. Any representation to the contrary is a criminal offense.

We have engaged H.C. Wainwright & Co., LLC, or the placement agent, as our exclusive placement agent in connection with this offering. The placement agent has no obligation to buy any of the securities from us or to arrange for the purchase or sale of any specific number or dollar amount of securities. We have agreed to pay the placement agent the placement agent fees set forth in the table below. See "Plan of Distribution" beginning on page S-12 of this prospectus supplement for more information regarding these arrangements.

						Per Pre-Funded
			Per Share			Warrant			Total
Offering price		$	3.055		$	3.054		$	1,349,721.55
Placement agent fees (1)	$	0.2139	$	0.2139	$	94,500.10
Proceeds, before expenses, to us (2)	$	2.8411	$	2.8401	$	1,255,221.45
(1)

In addition, we have agreed to pay the placement agent a management fee equal to 1.0% of the gross proceeds raised in this offering and to pay a non-accountable expense allowance of $85,000. In addition, we have agreed to issue to the placement agent unregistered warrants to purchase a number of shares of common stock equal to 7% of the aggregate number of shares of common stock and pre-funded warrants sold in this offering. See "Plan of Distribution" beginning on page S-12 of this prospectus supplement.

1. The amount of the offering proceeds to us presented in this table does not include proceeds from the sale of the unregistered pre- funded warrants and warrants in the concurrent private placements nor does it give effect to any exercise of any such warrants.

Delivery of the securities issued pursuant to this prospectus supplement and accompanying prospectus is expected to be made on or about January 12, 2023, subject to the satisfaction of certain closing conditions.

H.C. Wainwright & Co.

The date of this prospectus supplement is January 10, 2023

TABLE OF CONTENTS
Prospectus Supplement
	PAGE
About this Prospectus	ii
Cautionary Statement Regarding Forward-looking Statements	iii
Prospectus Summary	S-1
Risk Factors	S-6
Use of Proceeds	S-8
Dividend Policy	S-9
Description of the Securities We are Offering	S-10
Capitalization	S-11
Plan of Distribution	S-12
Concurrent Private Placements of Shares and Warrants	S-14
Legal Matters	S-15
Experts	S-15
Where You Can Find More Information	S-15
Prospectus
	Page
ABOUT THIS PROSPECTUS	1
OUR BUSINESS	2
RISK FACTORS	3
FORWARD-LOOKING STATEMENTS	3
USE OF PROCEEDS	4
THE SECURITIES WE MAY OFFER	4
DESCRIPTION OF CAPITAL STOCK	5
DESCRIPTION OF DEBT SECURITIES	7
DESCRIPTION OF WARRANTS	13
DESCRIPTION OF UNITS	15
LEGAL OWNERSHIP OF SECURITIES	16
PLAN OF DISTRIBUTION	19
LEGAL MATTERS	22
EXPERTS	22
WHERE YOU CAN FIND MORE INFORMATION	22
INCORPORATION OF DOCUMENTS BY REFERENCE	23

i

ABOUT THIS PROSPECTUS SUPPLEMENT

This document is in two parts. The first part is this prospectus supplement, which describes the terms of this offering and also adds to and updates information contained in the accompanying prospectus and the documents incorporated by reference into this prospectus supplement and the accompanying prospectus concerning My Size, Inc. The second part is the accompanying prospectus, dated December 30, 2020, including the documents incorporated by reference therein, which provides more general information, some of which may not apply to this offering. Generally, when we refer to this prospectus, we are referring to both parts of this document combined together with all documents incorporated by reference. If the description of the offering varies between this prospectus supplement, on the one hand, and the accompanying prospectus, or in any document incorporated by reference that was filed with the Securities and Exchange Commission, or SEC, before the date of this prospectus supplement, on the other hand, you should rely on the information contained in this prospectus supplement. However, if any statement in one of these documents is inconsistent with a statement in another document having a later date - for example, a document incorporated by reference into this prospectus supplement or the accompanying prospectus - the statement in the document having the later date modifies or supersedes the earlier statement.

We further note that the representations, warranties and covenants made by us in any agreement that is filed as an exhibit to any document that is incorporated by reference herein were made solely for the benefit of the parties to such agreement, including, in some cases, for the purpose of allocating risk among the parties to such agreements, and should not be deemed to be a representation, warranty or covenant to you. Moreover, such representations, warranties or covenants were accurate only as of the date when made. Accordingly, such representations, warranties and covenants should not be relied on as accurately representing the current state of our affairs.

You should rely only on the information contained in or incorporated by reference into this prospectus supplement or contained in or incorporated by reference into the accompanying prospectus to which we have referred you. Neither we nor the placement agent have authorized anyone to provide you with information that is different. If anyone provides you with different or inconsistent information, you should not rely on it. We may authorize one or more "free writing prospectuses" (i.e. written communications concerning the offering that are not part of this prospectus supplement) that may contain certain material information relating to this offering. The information contained in, or incorporated by reference into, this prospectus supplement and contained in, or incorporated by reference into, the accompanying prospectus is accurate only as of the respective dates thereof, regardless of the time of delivery of this prospectus supplement and the accompanying prospectus or of any sale of securities. It is important for you to read and consider all information contained in this prospectus supplement and the accompanying prospectus, including the documents incorporated by reference herein and therein, in making your investment decision. You should also read and consider the information in the documents to which we have referred you under the captions "Where You Can Find More Information" and "Incorporation of Documents by Reference" in this prospectus supplement and in the accompanying prospectus.

We are offering to sell, and are seeking offers to buy, securities only in jurisdictions where such offers and sales are permitted. The distribution of this prospectus supplement and the accompanying prospectus and the offering of securities in certain jurisdictions or to certain persons within such jurisdictions may be restricted by law. Persons outside the United States who come into possession of this prospectus supplement and the accompanying prospectus must inform themselves about and observe any restrictions relating to the offering of securities and the distribution of this prospectus supplement and the accompanying prospectus outside the United States. This prospectus supplement and the accompanying prospectus do not constitute, and may not be used in connection with, an offer to sell, or a solicitation of an offer to buy, any securities offered by this prospectus supplement and the accompanying prospectus by any person in any jurisdiction in which it is unlawful for such person to make such an offer or solicitation.

These securities are not being offered in Israel. This offering or this prospectus are not, and under no circumstances are to be construed as, an advertisement or a public offering of securities in Israel. Any public offer or sale of securities in Israel may be made only in accordance with the Israeli Securities Law 5728-1968, or the Israeli Securities Law (which requires, among other things, the filing of a prospectus in Israel or an exemption therefrom). This document does not constitute a prospectus under the Israeli

Securities Law and has not been filed with or approved by the Israel Securities Authority.

ii

CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS

This prospectus supplement and any accompanying prospectus, including the documents that we incorporate by reference, contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, or the Securities Act, and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Such forward-looking statements include those that express plans, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact. These forward-looking statements are based on our current expectations and projections about future events and they are subject to risks and uncertainties known and unknown that could cause actual results and developments to differ materially from those expressed or implied in such statements.

In some cases, you can identify forward-looking statements by terminology, such as "expects," "anticipates," "intends," "estimates," "plans," "believes," "seeks," "may," "should," "could" or the negative of such terms or other similar expressions. Accordingly, these statements involve estimates, assumptions and uncertainties that could cause actual results to differ materially from those expressed in such statements. Any forward-looking statements are only estimates or predictions of future events based on information currently available to our management and management's current beliefs about the potential outcome of future events.

You should read this prospectus supplement, the accompanying prospectus and the documents that we reference herein and therein and have filed as exhibits to the registration statement, of which this prospectus supplement forms a part, completely and with the understanding that our actual future results may be materially different from what we expect. You should assume that the information appearing in this prospectus supplement and any accompanying prospectus is accurate as of the date on the front cover of this prospectus supplement. Because the risk factors referred to above, as well as the risk factors referred to on page S-6 of this prospectus supplement and incorporated herein by reference, could cause actual results or outcomes to differ materially from those expressed in any forward-looking statements made by us or on our behalf, you should not place undue reliance on any forward-looking statements. Further, any forward-looking statement speaks only as of the date on which it is made, and except as may be required under applicable securities laws, we undertake no obligation to update any forward-looking statement to reflect events or circumstances after the date on which the statement is made or to reflect the occurrence of unanticipated events. New factors emerge from time to time, and it is not possible for us to predict which factors will arise. In addition, we cannot assess the impact of each factor on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward- looking statements. We qualify all of the information presented in this prospectus supplement and the accompanying prospectus, and particularly our forward-looking statements, by these cautionary statements.

iii